Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.
Ther Adv Med Oncol
; 12: 1758835920922051, 2020.
Article
en En
| MEDLINE
| ID: mdl-32547646
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Año:
2020
Tipo del documento:
Article